Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
NCT07270601
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- NAFLD - Non-Alcoholic Fatty Liver Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- ContextVision AB
- Last updated on ClinicalTrials.gov
- December 8, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- University of Washington · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.